This study examines the long-term OS of relapsed AML patients who were enrolled to 9 successive ECOG-ACRIN trials for newly diagnosed AML, during 1984AML, during -2008. The objectives were to examine whether there is a trend of improvement in the survival of relapsed AML patients in the more recent studies and to search for prognostic factors that are associated with long-term OS after relapse. A total of 3012 patients were enrolled, 1779 (59.1%) achieved CR1 and of these, 58.9% relapsed. The median follow-up was 9.7 years. The median OS from relapse was 0.5 years and the 5-year OS was 10 (61)%. These results were similar even for the most recent studies. A multivariate model showed that age, cytogenetics at diagnosis, duration of CR1 and undergoing allogeneic transplantation were significantly associated with OS from relapse. Even among patients who relapsed with better prognostic factors; age < 40 and CR1 > 12 months, there was no significant OS difference between the studies. In conclusion, this large cohort appears to confirm that the survival of AML patients postrelapse continues to be dismal and has not improved during the past quarter of a century. sis and cytogenetic analysis, the objectives of this study were to examine whether there is a trend of change in the survival of relapsed AML patients in the more recent studies and to search for prognostic factors that are associated with long-term OS after relapse.
| I N T R O D U C T I O N
Relapse after achieving a complete remission (CR) in acute myeloid leukemia (AML) portends for a poor prognosis and allogeneic hematopoietic cell transplantation (Allo-HCT) after achieving a second remission likely offers the only possible chance for cure. While approximately 40%-55% of patients who experience disease relapse may achieve a second CR, only 10%-20% have a chance of long-term survival. [1] [2] [3] This study examines the long-term overall survival (OS) of AML patients (not including acute promyelocytic leukemia) who experienced leukemia relapse after achieving first CR (CR1). It is based on nine successive trials for newly diagnosed AML patients (E3483, E3489, PC486, E3993, E4995, E1490,
E3997, E1900, and E3999), conducted by the ECOG-ACRIN Cancer
Research Group between March 1984 to November 2008. Recognizing the many changes that have taken place on time in the diagnosis, prognosis and cytogenetic analysis, the objectives of this study were to examine whether there is a trend of change in the survival of relapsed AML patients in the more recent studies and to search for prognostic factors that are associated with long-term OS after relapse.
| M E T H O D S

| Patient population
Between 1984 and 2008, 3012 patients, aged 15 years and older, who had untreated AML were enrolled on 9 consecutive, phase II and III, ECOG-ACRIN-led clinical trials. [4] [5] [6] [7] [8] [9] [10] [11] [12] The treatment protocols, their activation dates and accrual numbers are summarized in Table 1 .
Acute promyelocytic leukemia patients were included in the older AML studies but are excluded from this analysis due to the unique behavior and treatment of this disease. Each protocol was approved by the Institutional Review Boards at each respective institution. All patients signed a written informed consent.
| Cytogenetic risk classification
Cytogenetic risk was classified as "favorable," "intermediate," "unfavora- Minimal cytogenetic information was available for patients enrolled on the following earlier protocols: E1490, E3483, and PC486, consistent with the less than optimal cytogenetic data during this period. All cytogenetic data that will be presented in this manuscript are from time of diagnosis and not from time of relapse.
| Hematopoietic cell transplantation (HCT)
Among the 9 studies, HCT was part of the treatment regimen in 5 studies (E3483, E3489, PC486, E4995, E1900) and patients were classified according to the type of transplant received. In most cases, HCT was performed as part of protocol treatment. However, if a patient's record had a definitive comment indicating that the patient received HCT off-protocol, i.e., not part of the prescribed therapy, this information was applied. All other patients were classified as "no transplant".
| Statistical analysis
OS was defined as time from first relapse to death from any cause.
Kaplan-Meier estimates were used to estimate the event-time distributions for OS. Multivariate model stratified on protocol were used to examine whether the following factors are prognostic for OS from relapse: age, gender, cytogenetic risk, ECOG performance status, WBC count, platelets, hemoglobin, marrow blasts, peripheral blood blasts, duration of CR1 and whether patients received transplant while in CR1. If > 10% of patients had a missing value for a particular covariate, an indicator for whether or not the covariate was missing was indicated in the multivariate mode. All P values were based on 2-sided tests.
| RE SUL TS
A total of 3012 patients were enrolled in the 9 studies. Among those 3012 patients enrolled, 1779 (59.1%) achieved CR1 and of these, while in CR1.
The median OS from relapse was 0.5 years. The 2-and 5-year OS were 16(61)% and 10(61)%, respectively. These results were similar even for the most recent studies (E1900 and E3999) as the median OS rates were 0.6 and 0.4 years, respectively and the 5-year OS was 12 (6 2) and 5 (6 2)%, respectively (Table 3) . Gene mutation data were only available for part of the patients in E1900. Out of 652 patients enrolled on this study, 221 patients achieved CR and then relapsed. Among those with gene mutation data available, 32.8% had DNMT3A mutation, 25.1% had FLT-ITD mutation and 27% had NPM1 mutation. A multivariate analysis which included these 3 gene mutations (FLT3-ITD, DNMT3A, and NPM1) revealed that only FLT3-ITD had statistically significant impact on prognosis.
Finally, we focused on patients who relapsed with better prognostic factors; age younger than 40 and CR1 duration of more than 12 months. A comparison of OS of these patients among the different studies during the years revealed no statistically significant difference (P 5 .48, Figure 4 ). 
| DISCUSSION
The first goal of this study was to examine whether in more recent studies there is an improvement in the survival of AML patients whose disease relapses after achieving a first remission. Our analysis demonstrates that there has been no change in the poor prognosis of relapsed AML patients over the last 25 years. Allogeneic HCT is the only curative option for relapsed AML patients, but only 40%-55% of the patients achieve a second CR and only about 50%-70% of those who While we realize the limitations of this study, such as the absence of data regarding treatment at relapse, achievement of CR2 as well as disease free survival from CR2, and the incompleteness of cytogenetic data, it is the most striking finding of this analysis that the prognosis of relapsed AML has not improved over the last 25 years.
It should be emphasized that the lack of improvement in the survival of relapsed patients is true even in patients with relatively better prognostic factors; the OS of patients younger than age 40 with CR1 duration of more than 1 year was not improved with recent studies, despite the introduction of some therapeutic modifications and targeted agents (e.g., higher anthracycline doses and gemtuzumab ozogamicin). Long-term survival was observed in less than 10% of patients.
These were patients who survived the relapse, achieved a second CR and then successfully underwent an allogeneic transplant. These data are crucial when considering postremission strategies, and suggest that offering a therapy most likely to lead to cure in CR1 is the preferred option. Nowadays, new strategies are being incorporated into AML treatment, as FLT3 inhibitors, IDH inhibitors and venetoclax. These agents were not available during the time period of the study and may change the future results of relapsed AML patients.
In conclusion, this study of a very large cohort of ECOG-ACRIN patients, appears to confirm that, unfortunately, the survival of AML patients postrelapse continues to be dismal and has not improved during the past quarter of a century. In addition, the current study demonstrates the prognostic impact of age, duration of CR1, cytogenetics at diagnosis and undergoing allo-HCT at first CR on the long term OS postrelapse.
